Celebrex & Possible Heart Problems
Find a Conversation
|Fri, 12-17-2004 - 8:41pm|
Patients receiving high doses at greater risk, study finds
By Amanda Gardner
FRIDAY, Dec. 17 (HealthDayNews) -- Pfizer Inc. said Friday that a study of its popular pain drug Celebrex in cancer patients had found an apparent increased risk of heart attack and other cardiovascular problems.
But a second, separate cancer trial, however, found no increased risk of heart problems tied to the drug.
The studies, conducted by the National Cancer Institute, uncovered the cardiovascular problems in patients enrolled in the so-called Adenoma Prevention with Celecoxib -- the generic name for Celebrex -- (APC) trial. No problems were found in patients taking part in the Prevention of Spontaneous Adenomatopus Polyps (PreSAP) trial.
In a statement released Friday morning, Pfizer said it was reviewing the data and warned against jumping to conclusions about the use of Celebrex for all types of patients. For instance, those patients enrolled in the two cancer trials were taking twice the dose recommended for people struggling with pain due to osteoarthritis, the company said.
"In placing this new information in context, it is important to understand that the APC trial results differ from both the PreSAP cardiovascular results as well as the large body of data that we and others have accumulated over time, in which an increased risk of serious cardiovascular events in arthritis patients, even at higher-than-recommended doses, had not been seen," said Dr. Joseph Feczko, president of worldwide development for Pfizer.
More on this story at:
IVHealth Ruth Ann
Assistant Community Moderator/Health Librarian